Results 41 to 50 of about 20,657 (229)
BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
Background: Intimal hyperplasia is a common cause of many vasculopathies. There has been a recent surge of interest in the bromo and extra-terminal (BET) epigenetic “readers” including BRD4 since the serendipitous discovery of JQ1(+), an inhibitor ...
Bowen Wang +6 more
doaj +1 more source
Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. [PDF]
The mammary epithelium depends on specific lineages and their stem and progenitor function to accommodate hormone-triggered physiological demands in the adult female.
Abe +111 more
core +2 more sources
The bromodomain and extra-terminal domain (BET) proteins are promising drug targets for cancer and immune diseases. However, BET inhibition effects have been studied more in the context of bromodomain-containing protein 4 (BRD4) than BRD2, and the BET ...
Lusy Handoko +13 more
doaj +1 more source
JQ1 and GSK2801 are bromo domain inhibitors (BDI) known to exhibit enhanced anti-cancer activity when combined with other agents. However, the underlying molecular mechanisms behind such enhanced activity remain unclear.
Nanda Kumar Yellapu +4 more
doaj +1 more source
Thermoelectric efficiency of three-terminal quantum thermal machines [PDF]
The efficiency of a thermal engine working in linear response regime in a multi-terminals configuration is discussed. For the generic three-terminal case, we provide a general definition of local and non-local transport coefficients: electrical and ...
Benenti, Giuliano +5 more
core +6 more sources
Open Access Could Transform Drug Discovery: A Case Study of JQ1 [PDF]
The cost to develop a new drug from target discovery to market is a staggering $1.8 billion, largely due to the very high attrition rate of drug candidates and the lengthy transition times during development. Open access is an emerging model of open innovation that places no restriction on the use of information and has the potential to accelerate the ...
Zeeshaan, Arshad +9 more
openaire +2 more sources
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC.
Yu Pan +8 more
doaj +1 more source
Effect of bet missense mutations on bromodomain function, inhibitor binding and stability [PDF]
Lysine acetylation is an important epigenetic mark regulating gene transcription and chromatin structure. Acetylated lysine residues are specifically recognized by bromodomains, small protein interaction modules that read these modification in a ...
Alessandra, Pasquo +7 more
core +2 more sources
Scalable syntheses of the BET bromodomain inhibitor JQ1
We have developed methods involving the use of alternate, safer reagents for the scalable syntheses of the potent BET bromodomain inhibitor JQ1. A one-pot three step method, involving the conversion of a benzodiazepine to a thioamde using Lawesson's reagent, followed by amidrazone formation and installation of the triazole moiety furnished JQ1.
Syeda, Shameem Sultana +2 more
openaire +2 more sources
BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
Most colorectal cancer (CRC) patients are insensitive to immune checkpoint inhibitors (ICIs) due to the immunosuppressive tumor microenvironment (TME). Epigenetic factors such as the bromo-and extraterminal domain (BET) family proteins may be responsible
Huijin Wang +10 more
semanticscholar +1 more source

